Efficacy of Mometasone Furoate in the Reduction of Moderate/Severe Radiation Dermatitis in Breast Cancer Patients Following Mastectomy

MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review

“…There is insufficient evidence supporting the use of other corticosteroids, such as hydrocortisone and beclomethasone. 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 Barrier films and dressings 25 (18) 1856 (39; 2–333) Mepitel® film (9); 3M™ Cavilon™ No-Sting Barrier Film (4); StrataXRT® (topical film-forming gel) (3); Silver nylon dressing (3); Other (6) Breast (15); Head and neck (6); Prostate (2); Other (2) Mepitel film and Hydrofilm were both generally found to be effective in ARD prevention. There was inconsistent evidence supporting the use of StrataXRT, silver nylon dressings, Cavilon No-Sting barrier film, and other interventions in ARD prevention.…”

“…A total of 18 studies assessed topical corticosteroids for the prevention of ARD, including three non-randomized studies and 15 RCTs 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 ( Appendix C, Table 2 ). Topical mometasone furoate (most commonly 0.1% potency) was evaluated in eight RCTs 56 , 57 , 58 , 59 , 60 , 61 , 62 , 72 and demonstrated efficacy across trials of both doubtful and adequate QoE in preventing overall ARD and erythema.…”

“…A total of 18 studies assessed topical corticosteroids for the prevention of ARD, including three non-randomized studies and 15 RCTs 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 ( Appendix C, Table 2 ). Topical mometasone furoate (most commonly 0.1% potency) was evaluated in eight RCTs 56 , 57 , 58 , 59 , 60 , 61 , 62 , 72 and demonstrated efficacy across trials of both doubtful and adequate QoE in preventing overall ARD and erythema. Betamethasone further demonstrated prophylactic efficacy in ARD prevention, 65 , 66 , 67 , 68 , 69 , 73 suggesting that the current evidence supports the use of both mometasone furoate and betamethasone in preventing ARD and associated symptoms.…”